Protalix BioTherapeutics, Inc. Deferred Revenue (Non-Current)
Protalix BioTherapeutics, Inc. (PLX) had Deferred Revenue (Non-Current) of $61.78 million as of 2018-09-30, per its 10-Q filed 2018-11-07.
Discontinued › Balance Sheet › Liabilities › Liabilities, Noncurrent › Liabilities, Other than Long-Term Debt, Noncurrent › Deferred Revenue, Noncurrent
us-gaap:DeferredRevenueNoncurrent · last filed 2018-11-07
- 2018-09-30: Deferred Revenue, Noncurrent $61.78M.
- 2018-06-30: Deferred Revenue, Noncurrent $31.89M.
- 2018-03-31: Deferred Revenue, Noncurrent $29.03M.
- 2017-12-31: Deferred Revenue, Noncurrent $26.85M.
| Period end | Deferred Revenue, Noncurrent |
|---|---|
| 2018-09-30 | $61.78M 10-Q · filed 2018-11-07 |
| 2018-06-30 | $31.89M 10-Q · filed 2018-08-09 |
| 2018-03-31 | $29.03M 10-Q · filed 2018-05-09 |
| 2017-12-31 | $26.85M 10-Q · filed 2018-11-07 |
| 2016-09-30 | $453.00K 10-Q · filed 2016-11-09 |
| 2016-06-30 | $617.00K 10-Q · filed 2016-08-08 |
| 2016-03-31 | $744.00K 10-Q · filed 2016-05-09 |
| 2015-12-31 | $744.00K 10-K · filed 2017-03-16 |
| 2015-09-30 | $35.13M 10-Q · filed 2015-11-09 |
| 2015-06-30 | $35.61M 10-Q · filed 2015-08-10 |
| 2015-03-31 | $36.89M 10-Q · filed 2015-05-07 |
| 2014-12-31 | $37.23M 10-Q · filed 2015-11-09 |
| 2014-09-30 | $38.37M 10-Q · filed 2014-11-10 |
| 2014-06-30 | $39.51M 10-Q · filed 2014-08-07 |
| 2014-03-31 | $40.66M 10-Q · filed 2014-05-08 |
| 2013-12-31 | $41.80M 10-K · filed 2015-03-12 |
| 2013-09-30 | $43.42M 10-Q · filed 2013-11-07 |
| 2013-06-30 | $45.12M 10-Q · filed 2013-08-08 |
| 2013-03-31 | $46.99M 10-Q · filed 2013-05-09 |
| 2012-12-31 | $48.89M 10-K · filed 2014-03-13 |
| 2012-09-30 | $47.50M 10-Q · filed 2012-11-07 |
| 2012-06-30 | $48.64M 10-Q · filed 2012-08-03 |
| 2012-03-31 | $49.78M 10-Q · filed 2012-05-09 |
| 2011-12-31 | $50.92M 10-K · filed 2013-02-28 |
| 2011-09-30 | $53.42M 10-Q · filed 2011-11-07 |
| 2011-06-30 | $54.05M 10-Q · filed 2011-08-08 |
| 2010-12-31 | $55.49M 10-K · filed 2012-02-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ANAVEX LIFE SCIENCES CORP. (AVXL) | United States | $0.218B | -18.37 |
| Alector, Inc. (ALEC) | United States | $0.213B | -1.90 |
| Compass Therapeutics, Inc. (CMPX) | United States | $0.204B | -5.35 |
| Aligos Therapeutics, Inc. (ALGS) | United States | $0.238B | -0.47 |
| Lineage Cell Therapeutics, Inc. (LCTX) | United States | $0.241B | -10.35 |
| Protara Therapeutics, Inc. (TARA) | United States | $0.198B | -3.22 |
| Alpha Cognition Inc. (ACOG) | $0.185B | -6.77 | |
| Coherus Oncology, Inc. (CHRS) | United States | $0.182B | -1.63 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |
| PRECISION BIOSCIENCES INC (DTIL) | United States | $0.175B | -3.95 |